Clinical Trial: NCT03203473
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Toni Choueiri, MD |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-08-12 |
Study Overview
Brief Summary
This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer
The drugs involved in this study are:
Nivolumab Ipilimumab
Official Title
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Conditions
Renal Cancer
Intervention / Treatment
- Drug: Ipilimumab
- Drug: Nivolumab
Other Study ID Numbers
- 17-064
Start Date (Actual)
2017-10-26
Primary Completion Date (Actual)
2021-11-30
Study Completion Date (Estimated)
2026-12-28
Enrollment (Actual)
85
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Toni Choueiri, MD |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-08-12 |
Study Overview
Brief Summary
This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer
The drugs involved in this study are:
Nivolumab Ipilimumab
Official Title
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Conditions
Renal Cancer
Intervention / Treatment
- Drug: Ipilimumab
- Drug: Nivolumab
Other Study ID Numbers
- 17-064
Start Date (Actual)
2017-10-26
Primary Completion Date (Actual)
2021-11-30
Study Completion Date (Estimated)
2026-12-28
Enrollment (Actual)
85
Study Type
Interventional
Phase
Phase 2